Vital Therapies has secured $22.5 million in a round of financing from 15 investors. The San Diego company will use the money to further develop its ELAD bioartificial liver, which could provide continuous liver support for patients being treated for hepatitis B, alcohol hepatitis and acute organ failure.

Related Summaries